Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2024?
Market Rules
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861. This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile. According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day. However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2024. The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
The market will resolve as 'Yes' if tdi-11861 is approved for human clinical trials at any point in 2024 or before, and 'No' if it does not.